Cassiopea announces filing for delisting of its registered shares from SIX Swiss Exchange

Cassiopea S.p.A. / Key word(s): Delisting

04-Feb-2022 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

Lainate, Italy, February 4, 2022: Cassiopea S.p.A. (SIX: SKIN) ('Cassiopea') today announced that it has filed for delisting of its registered shares from SIX Swiss Exchange ('SIX'). Cassiopea has applied for a last trading day on March 4, 2022, which is subject to the approval by SIX.

About Cassiopea
Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to optimize the commercial potential for its products with commercial partners. For further information on Cassiopea, please visit www.cassiopea.com.

Contact

Cassiopea SpA

Pierpaolo Guzzo, CEO
Tel              +39 02 868 911 24 
E-mail        pguzzo@cassiopea.com